This trial is evaluating whether MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) will improve 1 primary outcome in patients with Cognitive Decline. Measurement will happen over the course of baseline, 8 weeks, 12 weeks.
This trial requires 166 total participants across 2 different treatment groups
This trial involves 2 different treatments. MagVenture MagProX100 Stimulator (MagVenture, Falun, Denmark) is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Cognitive decline results in problems in the ability to read and with thinking and remembering things. Reduced motivation, apathy, and problems solving are also signs of the changes that may occur in the person with the disease. The use of medications has a major impact on people with cognitive decline.
This group of factors does not create a complete explanation for an individual's cognitive decline. There are undoubtedly multiple contributing factors including brain injury, chronic alcoholism, and use of certain drugs. Cognitive decline is associated with increased risk of dementia and stroke, both of which may result in disability. This group of factors are potentially modifyable.
The ability of older people to learn to cope with new situations can improve over many years. Research should investigate the effectiveness of specific learning strategies and the use of medications to treat cognitive decline, and the effectiveness of interventions to increase confidence in dealing in the community.
Each year, around 1 million US adults experience significant declines in one or more cognitive abilities and ~2.5 million experience declines in one or more activities of daily living.
Cognitive decline in Alzheimer's disease patients is characterised by a deficit in executive functions, and more specifically in working memory, which seems to be primarily linked to damage of the frontal lobes and the cingulate.
This treatment is not based on evidence from randomized controlled trials or systematic reviews. Therefore, the safety and efficacy of treatments for cognitive decline have yet to be defined.\n
Given the absence of efficacy observed by two independent studies, this product is not a suitable for treating postmenopausal hypoactive bladder. The product's labeling and promotion, however, are misleading.
Cognitive decline is highly prevalent, is not family sensitive, and is associated with the presence or absence of objective, but not subjective, cognitive impairment. Such findings are similar to those of prior neuropsychologic and neuroimaging studies demonstrating no familial liability to dementia associated with vascular risk factors. Therefore, cognitive decline is more likely a secondary rather than primary outcome for familial AD, but research in these areas should be expanded to other disorders of cognitive reserve.
Magventure® is indicated for pain alleviation. Based on our findings we cannot recommend any other side effects. The only side effect which can be observed is an increase of the pulse rate. This will vanish during the treatment span. Although it is not dangerous, it has to be considered at the end when switching patients for a different treatment which does not have this effect on the pulse rate.
In all patients, after an increase in the number of electrodes and of the duration of stimulation, a significant improvement was observed in cognitive and psychomotor function, as well as in health and quality of life in patients with mild to moderate Alzheimer's disease.
On average, participants with cognitive decline begin to show deterioration in executive function in their middle age. One in four of participants with baseline mild cognitive impairment will have mild cognitive decline during the aging years.
The FDA approved the magventure magprox100 stimulator in July 2016 for the treatment of patients with severe memory loss and dementia due to Alzheimer's disease. magprox100 is a non-invasive therapeutic system based on the neuroenhancer, M-300, which acts as a neural stem cell activator and neuroplasticity enhancer through its endogenous neurotransmitter (dopamine) release. The clinical development of M-300 was approved by the FDA in February 2013, and was originally referred to as M-300-C.